Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958421 | 0.85 | RARB (0.39) | PTGS2MEN1MAPTRAB9AKMT2A | |
| SCHEMBL4961528 | 0.84 | RAB9A (0.36) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4957814 | 0.84 | HTR2C (0.36) | PTGS2MEN1MAPTRAB9AKMT2A | |
| SCHEMBL5152024 | 0.83 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL5152028 | 0.83 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL3868895 | 0.83 | PTGS2 (0.52) | PTGS2NR1H4 | |
| SCHEMBL4958823 | 0.82 | HTR2C (0.38) | PTGS2MEN1MAPTRAB9AKMT2A | |
| SCHEMBL4963869 | 0.78 | HTR2C (0.36) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4961399 | 0.74 | P2RY14 (0.33) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4960908 | 0.74 | FAAH (0.46) | KMT2ASLC5A1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542972-A4 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885MEN1 4470/4885MAPT 3970/4885 |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGS1 | PTGS2 1/4885MEN1 4597/4885MAPT 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.